“Throughout the third quarter, we made important steps advancing our two lead gene therapy programs to provide transformative treatments to patients with serious genetic cardiomyopathies,” said Faraz Ali, Chief Executive Officer of Tenaya. “TN-201 and TN-401 each received positive recommendations from their respective Data Safety Monitoring Boards to advance into the dose expansion cohorts reflecting confidence in each product’s emerging safety profile. We were particularly pleased with the positive safety and promising clinical data presented on TN-201 as a potential treatment for MYBPC3-associated HCM at the recent AHA Scientific Sessions. We also look forward to sharing meaningful safety and interim biopsy and efficacy data from the RIDGE-1 trial of TN-401 for patients with PKP2-associated ARVC in the coming weeks.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Promising Clinical Developments and Regulatory Optimism Drive Buy Rating for Tenaya Therapeutics
- Tenaya Therapeutics presents new interim safety, efficacy data on TN-201
- FDA Places Hold on Tenaya’s MyPEAKTM-1 Trial
- Promising Developments in Tenaya Therapeutics’ MyPEAK-1 Study Support Buy Rating
- Tenaya Therapeutics Advances Genetic Therapy for Heart Disease: A Closer Look at the TN-201 Study